DATE : 16-03-14 14:30
|
A prospective, randomized comparison of promus everolimus-eluting and TAXUS Liberte paclitaxel-eluting stent systems in patients with coronary artery disease eligible for percutaneous coronary intervention: the PROMISE study.
|
|
|
WRITER :
stent
 HIT : 2,394
|
 C156._J_Korean_Med_Sci._2013;28_11_1609-1614..pdf (243.1K) [0] DATE : 2016-03-14 14:30:58 |
C156. Kim U, Lee CH, Jo JH, Lee HW, Choi YJ, Son JW, Lee SH, Park JS, Shin DG, Kim YJ, Jeong MH, Cho MC, Bae JH, Lee JH, Kang TS, Jung KT, Jung KH, Lee SW, Cho JH, Kim W, Hur SH, Kim KS, Park HS, Kim MH, Hwang JY, Kim DI, Kim TI; A prospective, randomized comparison of promus everolimus-eluting and TAXUS Liberte paclitaxel-eluting stent systems in patients with coronary artery disease eligible for percutaneous coronary intervention: the PROMISE study. J Korean Med Sci. 2013;28(11)1609-1614.
(Abstract)
We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion revascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n=425) and PES (n=425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (P for non-inferiority=0.021). MACE rates were significantly different; 5.6% in PES and 2.5% in EES (P = 0.027). Rates of MI (0.8% in PES vs 0.2% in EES, P = 0.308), all deaths (1.5% in PES vs 1.2% in EES, P = 0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES, P = 0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR.
|
|
